Patients with HS on adalimumab have a 53% higher risk of serious infections than those with psoriasis. HS patients are more prone to sepsis and genitourinary infections, with longer hospital stays.

Exton, Pennsylvania, Jan. 10, 2024 (GLOBE NEWSWIRE) -- In late October 2023, the FDA granted approval to Novartis' Cosentyx (secukinumab) for treating hidradenitis suppurativa (HS), marking it as the ...

Yuflyma (adalimumab-aaty) and its unbranded version may now be prescribed for HS in patients 12 years and older and for UV in children 2 years and older. The Food and Drug Administration (FDA) has ...

"Adalimumab, regardless of HiSCR responder status, was associated with improvements in common hematologic abnormalities," the authors wrote, adding that "these findings highlight the high inflammatory ...

Serum C-reactive protein is being investigated as a biomarker to predict adalimumab response in hidradenitis suppurativa patients. Elevated baseline C-reactive protein levels correlate with a reduced ...

To clear the air from the outset, treating hidradenitis suppurativa (HS) has always been challenging. Many patients delay seeking treatment until the condition has reached moderate or severe stages.

Add a second biologic or JAK1 inhibitor to biologic monotherapyAvoid adding an IL-1 inhibitor, which could raise infection risk ...

Hidradenitis suppurativa (HS), a not-so-rare skin disease, is coming out of the closet, so to speak. Affecting an estimated 3.3 million Americans, HS manifests itself through permanent scarring, ...

Please provide your email address to receive an email when new articles are posted on . Simlandi (adalimumab-ryvk) hit the market as first interchangeable, citrate-free Humira biosimilar in a ...